Menu Search
Equities

Giant Biogene Holding Co Ltd

2367:HKG.HS

Giant Biogene Holding Co Ltd

Actions
  • Price (HKD)51.55
  • Today's Change-2.95 / -5.41%
  • Shares traded8.15m
  • 1 Year change+47.50%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Giant Biogene Holding Co Ltd is a China-based investment holding company. The Company is principally engaged the research, development, manufacture and sale of bioactive material-based beauty and health products through its subsidiaries. The Company's main products include functional skincare products and medical dressings, and they are produced with recombinant collagen as the key bioactive ingredient. The Company also develops and manufactures rare ginsenosides technology-based functional foods. The Company mainly conducts its businesses within the domestic market.

  • Revenue in HKD (TTM)4.83bn
  • Net income in HKD1.91bn
  • Incorporated2021
  • Employees1.51k
  • Location
    Giant Biogene Holding Co LtdShanglin Yuan 7th RoadChang'An District, No. 1855XI'AN ChinaCHN
  • Websitehttp://www.xajuzi.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.